Drugs / AZD7442
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05166421 | Nov 2021 → Jul 2023 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04625972 | Dec 2020 → Apr 2021 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04625725 | Nov 2020 → Aug 2022 | COVID-19 | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD7442 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05166421 ↗ |
| Known as | Tixagevimab/Cilgavimab | “Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.” PMID 38703336 ↗ May 2024 |
| Modality | Monoclonal antibody | “AZD7442, a combination product of two monoclonal antibodies (AZD8895 and AZD1061)” NCT04625972 ↗ |
| Route | Intramuscular | “Single dose (× 2 IM injections) of 300 mg of AZD7442 on Day 1.” NCT04625972 ↗ |